Author of

• 25520

  +

  Poster Display session (Friday) (ID 65)

  • Event: ELCC 2018
  • Type: Poster Display session
  • Track:
  • Presentations: 2
  • Moderators:
  • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1

  • 25324

    +

    103P - Stereotactic body radiotherapy followed by radiofrequency ablation for inoperable stage Ib non-small cell lung cancer (ID 169)

    12:50 - 12:50  |  Author(s): Q. Zheng
    • Abstract

    Background:
    Hypoxia in the center of large tumor directly leads to radiation resistance. Concurrently, heat loss results in incomplete ablation oflarge tumors abutting airways or blood vessels. The combining stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) for non-small cell lung cancer (NSCLC) treatment could overcome respective shortcoming.
    
    Methods:
    In this study, we report our experience with combined SBRT and RFA in 27 medically inoperable patients with biopsy-proven T2aN0M0 NSCLC. Patients were treated with SBRT to a dose of 50 Gy followed by CT-guided RFA within 7 days.
    
    Results:
    There were no treatment-related deaths. At a mean follow-up period of 29.6 months (range, 3 to 56 months), 15 patients (55.6%) died, with 1-year, 2-year, and 3-year cumulative survival rates of 77.8%, 63.0% and 48.1%, respectively. Threeof the deaths were cancer related. Four (14.8%) and five (18.5%) patients had local and distant recurrence, respectively.
    
    Conclusions:
    We concluded that SBRT followed by RFA appears effective for centrally located NSCLC. Survival rates appear to be better than with SBRT or RFA alone. Interactions between the two modalities warrants deeper investigation.
    
    Clinical trial identification:
    
    
    Legal entity responsible for the study:
    N/A
    
    Funding:
    Has not received any funding
    
    Disclosure:
    All authors have declared no conflicts of interest.
    
    

  • 25331

    +

    113P - Exosomal miRNAs in peripheral blood as novel diagnostic biomarkers of radioresistant lung adenocarcinoma (ID 391)

    12:50 - 12:50  |  Author(s): Q. Zheng
    • Abstract

    Background:
    Radioresistance occurs in a high proportion of patients with lung adenocarcinoma (LA), resulting in poor response to radiation and dim prognosis. Early identification of radioresistance would accordingly guide adjustment of treatment regimens. Cell-derived exosomes containing proteins and nucleic acids can contribute to intercellular communication. Emerging evidence demonstrates exosomes are intimately involved in therapeutic resistance, and thus exosomes potentially can be used to predict radioresistance.
    
    Methods:
    Five patients with radioresistant LA and five healthy volunteers as negative controls were enrolled. Exosomes in 1 ml plasma were isolated with lipid nanoprobe approach, and miRNA from each sample was isolated with Qiagen miRNeasy kit. miRNA expression profiling was analyzed using microarrays, and quantitative real-time PCR was further used to validate miRNAs showing differential expression among two groups. Subsequently, selected miRNAs were validated in additional 27 patients with LA to evaluate their diagnostic potential.
    
    Results:
    Microarray analysis revealed there were 7 miRNAs expressed at a remarkably higher level in patients with radioresistant LA in comparison with that of healthy volunteers, and qRT-PCR further validated 3 miRNAs. Of note, exosomal miR-96-3p miR-10b-5p and miR-21 highly expressed in patients with radioresistant LA. The corresponding diagnostic specificity in predicting radioresistance was 0.916, 0.902 and 0.871, respectively. Moreover, exosomal miR-96-3p intensely indicates poor overall survival (with hazard ratio [95% confidence interval]: 2.38 (1.41–3.86), p < 0.001). However, it does not show significant correlation with tumor size and differentiation degree (p > 0.05).
    
    Conclusions:
    Our preliminary results indicate three exosomal miRNAs potentially can be used as non-invasive diagnosis biomarker of radioresistant LA.
    
    Clinical trial identification:
    
    
    Legal entity responsible for the study:
    International Ethical Guidelines for Biomedical Research Involving Human Subjects
    
    Funding:
    Youngth Programm of Natural Science Foundation of Jiangsu Province (BK20170134)
    
    Disclosure:
    All authors have declared no conflicts of interest.